The panel moderated by Dr Rueth explores the deescalation of chemotherapy for certain cancer types, showcasing better responses to targeted therapies.

It discusses advancements in drug antibody conjugates and the future of breast cancer treatment with directed therapies. Progress in targeted agents for triple negative breast cancer and the effectiveness of estrogen receptor modulators are highlighted.

The narrative emphasizes a shift towards less aggressive surgical approaches as systemic treatments improve.